ANIXA BIOSCIENCES, INC. Stock Issued During Period, Value, Other
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, other for the quarter ending 2021-10-31 was $0.00.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, other for the quarter ending 2021-07-31 was $0.00.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, other for the quarter ending 2021-04-30 was $20.29M.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, other for the quarter ending 2019-07-31 was $542.00K, a 51.11% decline year-over-year.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, other for fiscal 2021 was $20.29M.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, other for fiscal 2018 was $2.47M, a 28.62% decline from fiscal 2017.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, other for fiscal 2017 was $3.46M.
- ANIXA BIOSCIENCES, INC. stock issued during period, value, other for fiscal 2014 was $300.01K, a 21.22% decline from fiscal 2013.
| Period end | Stock Issued During Period, Value, Other 3 month | Stock Issued During Period, Value, Other 12 month |
|---|---|---|
| 2021-10-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-01-04 | $20.29M 10-K · filed 2023-01-04 |
| 2021-07-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-09-09 | |
| 2021-04-30 | $20.29M 10-Q · filed 2022-06-10 | |
| 2019-07-31 | $542.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-09-06 | $5.58M derived: sum of 4 quarters · filed 2019-09-06 |
| 2019-04-30 | $2.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-06-12 | $6.15M derived: sum of 4 quarters · filed 2019-06-12 |
| 2019-01-31 | $2.15M 10-Q · filed 2019-03-13 | |
| 2018-10-31 | $684.15K derived: 10-K 12 month − 10-Q 9 month · filed 2019-01-11 | $2.47M 10-K · filed 2019-01-11 |
| 2018-07-31 | $1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-09-07 | |
| 2017-10-31 | $3.46M 10-K · filed 2019-01-11 | |
| 2014-10-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-23 | $300.01K 10-K · filed 2015-12-23 |
| 2013-10-31 | $380.80K 10-K · filed 2015-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |